Robert F. Lutz

Abviva, Inc. develops and commercializes diagnostic and therapeutic products from Mammastatin, a growth-regulatory protein that inhibits breast cancer cell growth. The Mammastatin is normally present in the blood serum of healthy women and absent in women with breast cancer. The company develops breast cancer therapies through internal and external collaborative research with pharmaceutical, biotechnology and leading research institution world wide to commercialize the Mammastatin serum. It was founded on September 19, 1994 and is headquartered in Santa Barbara, CA.